Interactions between levodopa and other drugs: significance in the treatment of Parkinson's disease.
D000978:Antiparkinson Agents / Q000627:therapeutic use*; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001665:Binding Sites / Q000187:drug effects; D065098:Catechol O-Methyltransferase Inhibitors; D002395:Catecholamines / Q000378:metabolism; D055598:Chemical Phenomena; D002621:Chemistry; D004295:Dihydroxyphenylalanine / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000627:therapeutic use*; D004299:Dopamine beta-Hydroxylase / Q000037:antagonists & inhibitors; D004347:Drug Interactions; D005753:Gastric Mucosa / Q000378:metabolism; D006728:Hormones / Q000494:pharmacology; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D010276:Parasympatholytics / Q000494:pharmacology; D010277:Parasympathomimetics / Q000494:pharmacology; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism; D012702:Serotonin Antagonists
D000978:Antiparkinson Agents; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D065098:Catechol O-Methyltransferase Inhibitors; D002395:Catecholamines; D006728:Hormones; D008996:Monoamine Oxidase Inhibitors; D010276:Parasympatholytics; D010277:Parasympathomimetics; D012702:Serotonin Antagonists; D004295:Dihydroxyphenylalanine; D004299:Dopamine beta-Hydroxylase